Janssen Pharmaceuticals signed an agreement on April 7 with PeptiDream in which PeptiDream will use its peptide technology to identify and develop potential cardiovascular medications.
PeptiDream, based in Tokyo, will receive and undisclosed upfront payment and research funding. Janssen could also pay PeptiDream up to $1.15 billion in preclinical, clinical and commercialization milestone payments.
As part of the deal, PeptiDream will use its discovery platform system technology “to identify macrocyclic/constrained peptides against multiple metabolic and cardiovascular targets of interest selected by Janssen,” according to a news release.
Janssen has the right to develop and commercialize potential compounds that result from the agreement.
During the past seven years, PeptiDream has signed funded discovery collaborations with 16 pharmaceutical companies, including Amgen, AstraZeneca, Bristol-Myers-Squibb and Merck.
“Over the past few years PeptiDream has greatly expanded our ability to turn PDPS-identified peptide candidates into peptide therapeutics, small molecule drugs, and peptide drug conjugates (PDCs), and we greatly look forward to working with a world-renowned organization like Janssen to leverage these capabilities to discover and development the next generation of first-in-class and best-in-class therapeutics,” PeptiDream CEO and President Kiichi Kubota said in a news release.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.